Imatinib is an approved inhibitor of BCR-ABL, and KIT tyrosine kinase is used in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) and KIT-positive gastrointestinal stromal tumors (GIST), respectively [43,96]. Here, KIT is linked to chronic myelogenous leukemia, BCR-ABL1 positive.